<DOC>
	<DOCNO>NCT02463799</DOCNO>
	<brief_summary>This clinical trial study effect radium-223 add sipuleucel-T treat castrate-resistant prostate cancer spread bone . Sipuleucel-T autologous cellular immunotherapy design stimulate immune response prostate cancer . It suggest immune response may strengthen radiation therapy . Therefore study test whether radium-223 add sipuleucel-T increase immune response anti-tumor effect prostate cancer .</brief_summary>
	<brief_title>Ph 2 Study Sipuleucel-T W/ W/O Radium-223 Men With Asymptomatic Minimally Symptomatic Bone-MCRPC</brief_title>
	<detailed_description>This randomize study design ass antigen-specific immune response sipuleucel-T without radium-223 . Eligible subject register randomly assign 1:1 ratio receive sipuleucel-T radium-223 sipuleucel-T alone . Subjects arm ( sipuleucel-T radium ) undergo standard 1.5 2.0 blood volume leukapheresis , follow approximately 3 day later IV infusion sipuleucel-T . This process occur total 3 time approximately 2-week interval . Subjects Arm 1 receive total 6 infusion radium-223 IV dose 50 kBq/kg 4-week interval . All participant allow receive best supportive care include secondary hormonal manipulation require . No chemotherapy , external-beam radiation , radionuclides allow active treatment permit completion active treatment . Glucocorticoid-containing treatment minimize less equivalent dose prednisone 10mg daily feasible 3 month follow sipuleucel-T therapy . All patient continue medical surgical castration treatment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Written inform consent provide prior initiation study procedures 2 . Age ≥ 18 year 3 . Histologically documented adenocarcinoma prostate cancer confirm pathology report prostate biopsy radical prostatectomy specimen . If prostatic tumor mixed histology , &gt; 50 % tumor must adenocarcinoma 4 . Bone metastasis manifest one lesion bone scan perform within 2 month screen 5 . Castrateresistant prostate cancer , set castrate level testosterone ( ≤ 50 ng/dL ) , define current historical evidence disease progression concomitant surgical castration androgen deprivation therapy ( ADT ) , demonstrate two consecutive rise PSA OR new lesion bone scan : PSA progression define 2 rise PSA value compare reference value , measure least 7 day apart second value ≥ 2 ng/mL [ 1 ] . It must document within 2 month screen . Appearance one new area abnormal uptake bone scan compare image study acquire castration therapy precastration study response . Increased uptake preexisting lesion bone scan constitute progression . It must document within 4 month screen 6 . Serum PSA ≥ 2.0 ng/mL 7 . Screening ECOG perf status ≤ 1 8 . Asymptomatic minimally symptomatic disease ( narcotic analgesic ; analgesic use allow ) 9 . Prior abiraterone enzalutamide permit , require 10 . Concurrent osteoclastinhibitory therapy ( zoledronic acid , denosumab ) permit patient stable dose least 1 month 11 . Adequate screen hematologic , renal , liver function evidence laboratory test result within follow range ≤ 28 day prior registration : Absolute neutrophil count ( ANC ) ≥ 1.5 x109/L Platelet count ≥ 100 x109/L Hemoglobin ≥ 10.0 g/dL Total bilirubin level ≤ 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN Albumin &gt; 25 g/L 1 . The presence know lung liver metastases great 1.0 cm long axis diameter 2 . The presence lymphadenopathy great 3 cm shortaxis diameter 3 . The presence know brain metastasis 4 . Spinal cord compression , imminent long bone fracture , condition , opinion investigator , likely require radiation therapy and/or steroid pain control active phase 5 . Previous treatment chemotherapy mCRPC ( adjuvant chemotherapy permit ) , chemotherapy reason within 2 year prior registration 6 . Intention receive chemotherapy within 6 month enrollment protocol therapy 7 . History radiation therapy , either via external beam brachytherapy within 28 day prior registration 8 . Systemic radiotherapy strontium89 , samarium153 , rhenium186 rhenium188 treatment bony metastasis within previous 24 week 9 . Prior history cancer ( except nonmelanoma skin cancer lowgrade lowstage urothelial cancer ) 10 . Use prednisone equivalent systemic corticosteroid within 2 week treatment . Use inhale , intranasal , intraarticular , topical steroid allow . Oral IV steroid prevent treat IV contrast reaction allow 11 . Use opioid analgesic cancerrelated pain 12 . Use experimental drug within 4 week treatment 13 . Uncontrolled medical condition include diabetes , heart failure , COPD , ulcerative colitis , Crohn 's disease 14 . Uncontrolled fecal incontinence 15 . Any medical intervention , condition , circumstance , opinion investigator , could compromise adherence study requirement otherwise compromise study 's objective</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostatic neoplasm</keyword>
	<keyword>castration-resistant</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>radium-223</keyword>
	<keyword>sipuleucel-T</keyword>
</DOC>